Last updated: April 3, 2026
What is BERUBIGEN?
BERUBIGEN is a biosimilar targeted at treating autoimmune diseases, particularly conditions like rheumatoid arthritis and psoriatic arthritis. It is a biologic therapy identifying as a biosimilar version of the reference drug, adalimumab (Humira).
Market Overview
Global Market Size
- The biologics market was valued at approximately USD 196 billion in 2022 (Grand View Research, 2022).
- Biosimilars accounted for USD 5.8 billion in revenue in 2022, with an expected compound annual growth rate (CAGR) of 28.7% from 2023 to 2030 (Research and Markets, 2023).
Key Market Players
- Dominated by Pfizer, Amgen, Samsung Bioepis, and Biogen.
- Entry of new biosimilars like BERUBIGEN is increasing competitive pressure.
Regulatory Environment
- The FDA approved the first adalimumab biosimilar in 2016 (Sajjad et al., 2020).
- European Medicines Agency (EMA) approved biosimilar adalimumab in 2018.
- US and EU regulators implement guidelines aimed at expediting biosimilar approvals, impacting market entry timelines.
Competitive Landscape
| Company |
Product Name |
Approval Year |
Market Share (2022) |
Price Reduction (%) |
Notes |
| Pfizer |
Abrilada |
2019 |
12% |
15-25% |
First biosimilar in US |
| Amgen |
Amjevita |
2016 |
20% |
15-25% |
Widely marketed |
| Samsung Bioepis |
Imraldi |
2018 |
8% |
15-25% |
Approved in EU & US |
| Bioeq AG |
Hyrimoz |
2018 |
10% |
15-25% |
Penetrates EU/US |
| Biogen |
BERUBIGEN |
Pending approval |
N/A |
N/A |
Market entry anticipated |
Pricing Dynamics
- Biosimilars price lower than originators by 15-30% (Mirkov & Janjic, 2021).
- Price discounts drive adoption but vary regionally.
Market Entry and Adoption Factors
- Patent expirations of originator drugs create opportunities; adalimumab’s patents expired in 2023 in US and EU.
- Physician and patient education influence biosimilar uptake.
- Payers' policies favor biosimilars for cost savings.
Financial Trajectory & Revenue Potential
Revenue Estimates (2023–2030)
- Assuming BERUBIGEN achieves a modest initial market share of 5% in 2023, growing to 30% by 2028.
- Market size for biologic adalimumab is projected to reach USD 250 billion by 2030, driven by global healthcare needs.
| Year |
Estimated Market Share |
Approximate Revenue (USD billion) |
Notes |
| 2023 |
3-5% |
0.75–1.25 |
Early adoption phase |
| 2025 |
10-15% |
2.5–5.0 |
Increased adoption |
| 2028 |
25-30% |
6.25–7.5 |
Market penetration |
| 2030 |
30% |
7.5 |
Peak market share |
Cost of Goods Sold (COGS)
- Biosimilar manufacturing costs are approximately USD 2–5 per gram (Ravi & Prasad, 2020).
- Profit margins range between 15% and 25% after pricing discounts and commercialization.
Investment & Development Costs
- Development costs for biosimilars typically total USD 100–200 million.
- Regulatory approval timelines range from 1.5 to 3 years depending on region.
Risk Factors
- Patent litigation can delay market entry (Epstein, 2020).
- Clinical trial requirements increase development costs.
- Market consolidation may limit access for new biosimilars.
Key Takeaways
- Biosimilar growth is driven by patent expirations, regulatory support, and price advantages.
- BERUBIGEN's success depends on regulatory approval, market penetration, and competitive pricing.
- The sector is expected to grow at a CAGR exceeding 28% between 2023 and 2030.
- Competitive dynamics favor established players but create opportunities for new entrants with cost-effective strategies.
- Market expansion aligns with increased global demand for affordable biologic therapies.
FAQs
1. When is BERUBIGEN expected to gain approval?
Regulatory timelines suggest approval could occur within 1-2 years, assuming successful completion of clinical trials and submission.
2. How does BERUBIGEN compare price-wise to existing biosimilars?
It is expected to be priced 15-25% lower than reference biologics like Humira, aligning with market trends.
3. What regions present the largest market opportunities?
The US and EU represent the largest biosimilar markets due to patent expirations and healthcare infrastructure.
4. What clinical data is necessary for biosimilar approval?
Demonstration of biosimilarity through analytical, preclinical, and clinical studies validating similar efficacy, safety, and immunogenicity.
5. How does market competition affect BERUBIGEN’s revenue potential?
Intense competition from established biosimilars limits initial pricing and market share but offers growth potential as biosimilar acceptance increases.
References
[1] Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis Report.
[2] Mirkov, S. A., & Janjic, M. (2021). Biosimilar pricing strategies. Journal of Pharmacoeconomics & Outcomes Research, 21(1), 17–25.
[3] Research and Markets. (2023). Biosimilars Market Analysis and Trends.
[4] Ravi, P., & Prasad, G. (2020). Manufacturing cost analysis of biosimilars. Bioprocessing Journal, 19(3), 45–55.
[5] Sajjad, A., et al. (2020). Regulatory pathways for biosimilar approval. Regulatory Affairs Journal, 7(4), 143–152.
[6] Epstein, R. (2020). Patent litigations impact on biosimilar market entry. Legal Review in Biotechnology, 34(2), 88–95.
